Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Bender

Showing results (91-100 of 94) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 94 results.
Nature Communications|August 8, 2022
Author Correction: Vascular surveillance by haptotactic blood platelets in inflammation and infectionLeo Nicolai, Karin Schiefelbein, Silvia Lipsky, et al.
Journal of Medicinal Chemistry|May 25, 2010
Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophreniaEmmanuel Pinard, Alexander Alanine, Daniela Alberati, et al.
Blood|January 20, 2022
CRLF3 plays a key role in the final stage of platelet genesis and is a potential therapeutic target for thrombocythemiaCavan Bennett, Moyra Lawrence, Jose A Guerrero, et al.
Research and Practice in Thrombosis and Haemostasis|July 21, 2020
Illustrated State-of-the-Art Capsules of the ISTH 2020 CongressRobert Ariens, Cecilia Becattini, Markus Bender, et al.
Pageof 10

Showing results (91-100 of 94) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 94 results.
Nature Communications|August 8, 2022
Author Correction: Vascular surveillance by haptotactic blood platelets in inflammation and infectionLeo Nicolai, Karin Schiefelbein, Silvia Lipsky, et al.
Journal of Medicinal Chemistry|May 25, 2010
Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophreniaEmmanuel Pinard, Alexander Alanine, Daniela Alberati, et al.
Blood|January 20, 2022
CRLF3 plays a key role in the final stage of platelet genesis and is a potential therapeutic target for thrombocythemiaCavan Bennett, Moyra Lawrence, Jose A Guerrero, et al.
Research and Practice in Thrombosis and Haemostasis|July 21, 2020
Illustrated State-of-the-Art Capsules of the ISTH 2020 CongressRobert Ariens, Cecilia Becattini, Markus Bender, et al.
Pageof 10